Monoclonal antibodies against calcitonin gene-related peptide (CGRP) or its receptor (CLR + RAMP1) offer considerable improvements over existing drugs in migraine prophylaxis and are the first designed to act on the trigeminal pain system. Erenumab is approved by the FDA and EMA and has reached the market since May 2018. Two antibodies, fremanezumab and galcanezumab, directed towards the CGRP ligand, were approved by the FDA in September 2018. NAME Eptinezumab, erenumab, fremanezumab, galcanezumab
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APPROVED FOR
Frequent episodic migraine and chronic migraine in patients aged 18 years or older.
TYPES
Fully human monoclonal antibody (erenumab, IgG2λ) or humanized antibody (eptinezumab, IgG1j; fremanezumab, IgG2j; galcanezumab, IgG4).
MOLECULAR TARGETS
Erenumab: Fusion between two antibodies, one directed towards the N-terminal of RAMP1 and the other towards the N-terminal of CLR, components of the CGRP receptor. Eptinezumab, fremanezumab, and galcanezumab: These monoclonal antibodies are directed towards different parts of CGRP.
CELLULAR TARGETS
Since they do not pass the blood-brain barrier they have an extracerebral site of action, possibly in the trigeminovascular system.
EFFECTS ON TARGETS
Inhibits the functional action at the target: either at the receptor or reduces available ligand. Years of life with disability Global age-standardized migraine prevalence 1985 CGRP is found to be a potent dilator, located in trigeminal system, and involvement in migraine suggested
1990
CGRP is shown to be released in acute migraine attacks 
